Related Topics
Directories :: Biotechnology and Pharmaceuticals
Business Development :: Consulting
Directories :: Biotechnology
Pharma Industry / Biotech Industry News From Medical News Today
Expanding Premature Infant Follow-Up Care Research With 5 New MedImmune Fellowship Grants
Tue, 14 Oct 2008 03:00:00 -0700
Five neonatology fellows have been awarded grants designed to stimulate interest and research in the area of follow-up care of the premature infant as part of MedImmune's Fellowship Program. The grants, which underscore MedImmune's commitment to expanding research within pediatric medicine, will provide each recipient's institution a $35,000 grant, totaling $175,000 in research funding.
New Data Shows Abbott's Bioabsorbable Drug Eluting Stent Is Absorbed Within Two Years - Leaving Behind Functioning Blood Vessels
Tue, 14 Oct 2008 00:00:00 -0700
Abbott (NYSE: ABT) announced two-year data from 30 patients in its ABSORB clinical trial, demonstrating that its bioabsorbable drug eluting stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries within two years, leaving behind blood vessels that appeared to move and function similar to unstented arteries.
Neurobiological Technologies Announces FDA Agreement To Consolidate Viprinex Phase 3 Trials Accelerating Time To Pivotal Data
Tue, 14 Oct 2008 00:00:00 -0700
Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced that following a meeting with the U.S. Food and Drug Administration to discuss the Viprinex(TM) (ancrod) Phase 3 clinical program for acute ischemic stroke, the company plans to consolidate and analyze data from its two concurrently running double-blind clinical trials into a single Phase 3 pivotal trial. This new plan will accelerate the timing of the trial's efficacy and safety data to mid-2009.
FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment For Routine Prophylaxis In Children With Hemophilia A
Tue, 14 Oct 2008 00:00:00 -0700
Bayer HealthCare LLC announced that the U.S. Food and Drug Administration (FDA) has approved routine prophylaxis with Kogenate(R) FS Antihemophilic Factor (Recombinant) to reduce the frequency of bleeding episodes and the risk of joint damage in patients aged 0-16 years with severe hemophilia A with no pre-existing joint damage.
Peregrine Pharmaceuticals' Anti-PS Technology Platform To Be Discussed At AIDS Vaccine 2008 Conference
Tue, 14 Oct 2008 00:00:00 -0700
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) a clinical stage biopharmaceutical company developing monoclonal antibodies for cancer and serious viral infections, reported the company's anti-phosphatidylserine (anti-PS) technology platform will be discussed in scientific sessions at the AIDS Vaccine 2008 conference in Cape Town, South Africa.
Tennessean Editorials, Opinions Discuss FDA Investigation Drug List
Mon, 13 Oct 2008 11:00:00 -0700
The Tennessean on Thursday published an editorial and two opinion pieces about an FDA decision to publish online a quarterly list of drugs being investigated for potential safety risks. Summaries appear below.
The Seattle Times: Biotech
News on biotechnology pharmaceutical from BioPortfolio.com
RXi Pharmaceuticals Obtains an Exclusive Worldwide License to Technology for the Oral Delivery of RNAi Therape
Yahoo!:
RXi Pharmaceuticals Obtains an Exclusive Worldwide License to Technology for the Oral Delivery of RNAi Therape
FinanzNachrichten.de:
A Financial Deals Industry Tracker Focusing on the Pharmaceuticals and Healthcare Market for 2008: Examine M&A
Pharma Live:
The Economist: Biotechnology
Medicine: Shooting down cancer
Thu, 11 Sep 2008 11:04:00 -0000
A theory linking the scourge to stem cells may offer new ways of treating this most terrifying of diseasesEVERY age is afraid of plagues. For the most part, such plagues have been infections. The rich world, though, has brought infectious disease under control and, AIDS aside, the memory dims with every generation. Instead, the fear of disease has transferred itself to cancer. How to prevent it, and how to treat it if prevention has failed, fills the health pages of the newspapers. How this or that celebrity won or lost his or her battle with it seems to fill much of the rest.The military metaphor is not confined to newspapers. It is 37 years since Richard Nixon, then America’s president, declared war on the disease. During that time, the prognosis for cancer patients has got a lot better. Scientists have refined old therapies and found new ones. Moreover, governments have waged a relentless public-health campaign against the biggest cause of cancer—the smoking of tobacco. The war, however, has never looked close to being won. Scan the horizon and there is no sign of a cure. ...
Cancer stem cells: The root of all evil?
Thu, 11 Sep 2008 11:04:00 -0000
Cancer may be caused by stem cells gone bad. If that proves to be correct, it should revolutionise treatmentMUCH of medical research is a hard slog for small reward. But, just occasionally, a finding revolutionises the field and cracks open a whole range of diseases. The discovery in the 19th century that many illnesses are caused by bacteria was one such. The unravelling of Mendelian genetics was another. It now seems likely that medical science is on the brink of a finding of equal significance. The underlying biology of that scourge of modern humanity, cancer, looks as though it is about to yield its main secret. If it does, it is possible that the headline-writer’s cliche, “a cure for cancer”, will come true over the years, just as the antibiotics that followed from the discovery of bacteria swept away previously lethal infectious diseases. The discovery—or, rather, the hypothesis that is now being tested—is that cancers grow from stem cells in the way that healthy organs do. A stem cell is one that, when it divides, produces two unequal daughters. One remains a stem cell while the other multiplies into the sorts of cells required by its organ. This matters for cancer because, at the moment, all the cells of a tumour are seen as more or less equivalent. Therapies designed to kill them do not distinguish between them. Success is defined as eliminating as many of them as possible, so those therapies have been refined to do just that. However, if all that the therapies are doing is killing the descendants of the non-stem-cell daughters, the problem has not been eliminated. Instead of attacking the many, you have to attack the few. That means aiming at the stem cells themselves. ...
Pharmaceuticals: Convergence or conflict?
Thu, 28 Aug 2008 11:35:36 -0000
Drug giants’ recent attempts to buy big biotech firms have provoked a backlashDALLIANCES between conventional pharmaceutical companies and biotechnology firms are nothing new. Big Pharma, eager to refill its emptying drug pipelines, has in recent years looked hopefully to biotech’s upstarts. The drugs giants have pursued all sorts of tie-ups, from alliances to licensing deals to outright purchases of a few smallish companies. But mindful of the sharp cultural differences between the two sorts of firms, they have generally avoided big acquisitions.Until now, that is. In recent weeks Roche, a Swiss pharmaceuticals giant, has made a surprise $44 billion bid for the 44% of Genentech, the world’s biggest biotech firm by stockmarket value, that it does not already own; and Bristol-Myers Squibb (BMS), an American drugs company, has offered $4.5 billion for the 83% of ImClone, an American biotech firm, that it does not already control. These attempts came on the heels of earlier deals in which AstraZeneca, a British drugs giant, bought MedImmune for $15.6 billion, and Takeda of Japan paid $8.8 billion for Millennium. ...
Websites
